Austedo Generic Name Deutetrabenazine DrugBank Accession Number DB12161 Background Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor …

Deutetrabenazine, sold under the brand name Austedo, is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia.

Mar 9, 2025 · Austedo package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions …

Jun 26, 2024 · How does Austedo work (mechanism of action)? Austedo works to lower neurotransmitter levels, which are chemicals in the body that are communicated between cells.

Deutetrabenazine (Austedo) can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of deutetrabenazine …

The studies described below were conducted with AUSTEDO tablets; adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets.

Mechanism of Action Deutetrabenazine exerts its action after getting metabolized to α-dihydrotetrabenazine (HTBZ) and β-HTBZ, its major metabolites that reversibly inhibit VMAT2, which …

Jul 17, 2024 · Deutetrabenazine, also known by its brand name Austedo, is a medication primarily used to treat involuntary movements (chorea) associated with Huntington's disease and tardive …

Feb 28, 2025 · AUSTEDO XR extended-release tablets and AUSTEDO tablets are formulated with deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor for oral administration.